2 Information about olaparib

Marketing authorisation indication

2.1 Olaparib (Lynparza, AstraZeneca) has a marketing authorisation as a 'monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2‑mutations who have HER2‑negative, high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for olaparib.


2.3 The list price is £2,317.50 per 56‑pack of 150 mg tablets (excluding VAT; BNF online accessed January 2023).

2.4 The company has a commercial arrangement. This makes olaparib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)